VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline GoInvest Network

✎ Contributed by Ty Griffin

VERAXA Biotech has reported new in vitro proof-of-concept data supporting its BiTAC-ADC technology, demonstrating selective activity against cancer cells while sparing healthy cells in early testing.
The company is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026.
VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells.
The company maintains a diversified oncology pipeline of antibody-based formats including antibody-drug conjugates (“ADCs”), T-cell engagers (“TCEs”), and other antibody-based formats.
VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).

The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, the results…